Hexarelin Research Guide (Preclinical Overview)
This comprehensive hexarelin research guide provides laboratory researchers with an in-depth analysis of Hexarelin's chemical architecture, receptor binding affinity, and preclinical mechanisms. Synthesized strictly for in vitro and animal model investigation, Hexarelin remains a critical tool for exploring growth hormone secretagogue signaling pathways and tissue response models.
Quick answer
This comprehensive hexarelin research guide provides laboratory researchers with an in-depth analysis of Hexarelin's chemical architecture, receptor binding affinity, and preclinical mechanisms. Synthesized strictly for in vitro and animal model investigation, Hexarelin remains a critical tool for exploring growth hormone secretagogue signaling pathways and tissue response models.
Key takeaways
- [Hexarelin](/research-peptides/hexarelin) (chemically identified as His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide classified within the growth hormone secretagogue (GHS) family.
- [Hexarelin](/research-peptides/hexarelin) possesses a chemical formula of C47H58N12O6 and a molecular mass of approximately 887.04 g/mol.
- The primary mechanism of [Hexarelin](/research-peptides/hexarelin) centers on its potent agonism at the Growth Hormone Secretagogue Receptor type 1a (GHSR-1a), a 7-transmembrane G-protein coupled receptor predominantly expressed in the anterior pituitary gland and hypothalamus.
- A distinguishing characteristic of [Hexarelin](/research-peptides/hexarelin) among small-molecule ghrelin mimetics is its unique binding affinity for the CD36 scavenger receptor (also known as fatty acid translocase).
Introduction and Historical Discovery of Hexarelin
Hexarelin (chemically identified as His-D-Trp-Ala-Trp-D-Phe-Lys-NH2) is a synthetic hexapeptide classified within the growth hormone secretagogue (GHS) family. Discovered during investigations into small-molecule growth hormone (GH) releasing peptides, Hexarelin was engineered as a structurally stabilized analog of GHRP-6. Early biochemical screenings demonstrated that modifying specific amino acid residues yielded a compound with enhanced metabolic stability against circulating peptidases and an intensified receptor binding profile.
Unlike endogenous peptidyl ligands such as ghrelin, Hexarelin incorporates non-natural D-amino acids (D-Trp and D-Phe) within its primary sequence. This structural alteration drastically extends its half-life in aqueous assay environments, allowing biomedical researchers to observe sustained receptor activation in vitro without rapid enzymatic degradation. As a pure research compound, Hexarelin serves as a model molecule for evaluating non-GHRH signaling mechanisms within neuroendocrine and cardiovascular research models.
Molecular Structure and Chemical Characteristics
Hexarelin possesses a chemical formula of C47H58N12O6 and a molecular mass of approximately 887.04 g/mol. As a synthetic hexapeptide, its sequence incorporates aromatic amino acid residues—specifically tryptophan and phenylalanine—which confer distinct hydrophobic properties and facilitate high-affinity hydrophobic interactions with target G-protein coupled receptors (GPCRs).
The inclusion of a C-terminal amide group (-NH2) neutralizes the carboxyl charge, enhancing lipid membrane association in cell culture models and preventing C-terminal carboxypeptidase cleavage. When examining growth hormone secretagogues in a laboratory setting, researchers note that Hexarelin demonstrates superior resistance to physiological pH variations compared to un-amidated natural peptides. For accurate analytical reconstitution, the compound is typically solubilized in sterile aqueous buffers or standard laboratory solvents.
Primary Mechanism of Action: GHSR-1a Agonism
The primary mechanism of Hexarelin centers on its potent agonism at the Growth Hormone Secretagogue Receptor type 1a (GHSR-1a), a 7-transmembrane G-protein coupled receptor predominantly expressed in the anterior pituitary gland and hypothalamus. Binding of Hexarelin to GHSR-1a initiates a conformational change that activates the Gq/11 protein complex.
Preclinical studies suggest that this binding event triggers the activation of phospholipase C (PLC), resulting in the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PIP2) into inositol 1,4,5-trisphosphate (IP3) and diacylglycerol (DAG). IP3 subsequently mobilizes intracellular calcium storage from the endoplasmic reticulum, while DAG activates protein kinase C (PKC). In vitro pituitary cell assays demonstrate that this intracellular calcium surge stimulates the exocytosis of pre-stored growth hormone granules. Crucially, because Hexarelin operates through GHSR-1a rather than the Growth Hormone-Releasing Hormone Receptor (GHRHR), its signaling pathway is distinct from classic GHRH analogs, providing an independent biochemical pathway for laboratory study.
Secondary Binding Targets: CD36 Scavenger Receptor Activation
A distinguishing characteristic of Hexarelin among small-molecule ghrelin mimetics is its unique binding affinity for the CD36 scavenger receptor (also known as fatty acid translocase). CD36 is a multifunctional transmembrane glycoprotein expressed in cardiomyocytes, vascular endothelial cells, macrophages, and adipocytes.
In vitro data indicate that Hexarelin engages CD36 independently of its GHSR-1a activity. When bound to CD36 in cardiac tissue cultures, Hexarelin initiates intracellular signaling cascades involved in lipid transport, mitochondrial respiration, and oxidative stress modulation. Animal models evaluating ischemia-reperfusion injury show that CD36 engagement by Hexarelin helps preserve myocardial viability and reduce apoptosis in cardiac myocytes during oxygen deprivation. This dual affinity renders Hexarelin an invaluable double-target probe in cardiovascular preclinical research.
Comparative Analysis: Hexarelin vs. Other Secretagogues
When designing comparative endocrine assays, laboratory investigators often contrast Hexarelin with other synthetic ghrelin mimetics and growth hormone secretagogues. Below is an overview of how Hexarelin compares to closely related research compounds:
In preclinical model comparisons, Hexarelin exhibits higher receptor binding affinity and a stronger initial peak release profile than GHRP-6 or GHRP-2. However, Hexarelin is also subject to faster receptor desensitization (tachyphylaxis) upon repeated continuous exposure in vitro. Conversely, compounds such as Ipamorelin display higher selectivity for GHSR-1a without binding CD36, making Ipamorelin preferable for isolated endocrine studies, whereas Hexarelin is preferred when investigating cardiac tissue mechanisms. For dual-pathway investigations, researchers frequently pair secretagogues with GHRH analogs like CJC-1295 No DAC to examine synergistic receptor cross-talk.
Preclinical Applications in Cardiovascular and Endocrine Research
In scientific literature, Hexarelin is widely utilized in rodent models to study both acute pituitary secretion dynamics and localized tissue protection. In rodent somatotroph cultures, Hexarelin displays nanomolar potency in eliciting transient growth hormone release, allowing researchers to map downstream expression of Insulin-like Growth Factor 1 (IGF-1) mRNA and related anabolic signaling markers.
Cardiovascular research protocols utilize Hexarelin to investigate left ventricular function and vascular reactivity. Preclinical studies suggest that in perfused rat heart models (Langendorff preparations), Hexarelin administration prior to induced ischemia reduces infarct size, attenuates coronary perfusion pressure spikes, and limits lipid peroxidation. These actions appear driven by a combination of CD36 receptor binding and local activation of anti-apoptotic pathways (such as Akt/protein kinase B phosphorylation).
Metabolic and Musculoskeletal Studies in Animal Models
Beyond endocrine and cardiac assays, Hexarelin is evaluated in animal models of skeletal muscle atrophy and metabolic dysregulation. In rodent models subjected to dexamethasone-induced muscle wasting or cachexia, administration of Hexarelin has been shown to suppress the upregulation of muscle-specific E3 ubiquitin ligases (Atrogin-1 and MuRF1), thereby attenuating proteasomal degradation of myofibrillar proteins.
Furthermore, preclinical research indicates that Hexarelin plays a role in lipid metabolism and insulin sensitivity pathways. In high-fat diet rodent models, research groups utilize Hexarelin to track alterations in hepatic steatosis, circulating free fatty acids, and glucose tolerance, providing insights into modern metabolic syndrome pathways.
Laboratory Handling, Storage, and Reconstitution Standards
To maintain structural integrity and prevent hydrolytic cleavage, lyophylized Hexarelin must be handled under strict laboratory conditions. Lyophilized vials should be stored at -20°C or -80°C in a desiccated environment away from direct light. Under these conditions, the un-reconstituted peptide remains stable for extended periods.
For laboratory assay preparation, reconstitution should be performed using sterile laboratory-grade solvents such as bacteriostatic water (0.9% benzyl alcohol) or sterile normal saline. For precise step-by-step procedures regarding solvent addition and aliquot preparation, researchers can consult our detailed peptide reconstitution guide. Once reconstituted, liquid aliquots should be stored at 2°C to 8°C and utilized within a designated timeframe to minimize chemical degradation and aggregation.
Analytical Quality Assurance: HPLC, MS, and Endotoxin Verification
Accurate preclinical research requires reagents of uncompromised purity and verified sequence identity. PX1 Research subjects every batch of Hexarelin to rigorous analytical verification, including High-Performance Liquid Chromatography (HPLC) and Mass Spectrometry (MS). HPLC analysis ensures a chemical purity threshold of ≥98%, minimizing synthetic impurities or truncated peptide fragments that could introduce confounding variables into biological assays.
Mass spectrometry confirms the precise molecular mass (887.04 Da) and amino acid sequence profile. Additionally, because bacterial endotoxins (lipopolysaccharides) can invalidate cell culture and in vivo animal models by provoking non-specific immune responses, all PX1 Research lots undergo Limulus Amebocyte Lysate (LAL) testing to confirm endotoxin levels strictly below <0.01 EU/mg.
Sourcing Hexarelin from PX1 Research
PX1 Research is a dedicated USA-based supplier of high-purity research compounds engineered specifically for academic, institutional, and industrial laboratories. Our Hexarelin is USA-synthesized in state-of-the-art, GMP-compliant facilities and thoroughly evaluated by independent ISO 17025 accredited testing laboratories.
Every vial shipped is backed by a lot-specific Certificate of Analysis (COA) detailing exact HPLC purity percentages, MS spectra, and endotoxin assay results. To support uninterrupted experimental workflows, PX1 Research provides same-day dispatch (Monday through Friday) from our centralized distribution facilities in California and Arizona. Institutional buyers seeking bulk allocations for large-scale research projects can access our wholesale lab accounts program, or browse our comprehensive PX1 Research Library for technical documentation and analytical whitepapers.
Frequently Asked Questions
What is Hexarelin and what is its primary designation in research?
Hexarelin is a synthetic hexapeptide growth hormone secretagogue (GHS) designed for in vitro and preclinical laboratory research. It is supplied exclusively as a research chemical for scientific investigation and is not intended for human or clinical use.
How does Hexarelin differ from other growth hormone secretagogues like GHRP-6 and Ipamorelin?
Hexarelin demonstrates higher potency at the GHSR-1a receptor compared to GHRP-6, but causes faster receptor desensitization in vitro. Unlike Ipamorelin, Hexarelin also binds to the CD36 scavenger receptor, making it a unique probe for studying combined cardiac and endocrine pathways.
What specific receptor targets does Hexarelin engage in preclinical models?
Preclinical studies show that Hexarelin engages two main targets: the Growth Hormone Secretagogue Receptor (GHSR-1a) in pituitary and hypothalamic tissue, and the CD36 scavenger receptor in cardiac and vascular endothelial tissues.
How is Hexarelin quality and purity verified at PX1 Research?
Every lot of Hexarelin undergoes analytical testing via High-Performance Liquid Chromatography (HPLC) to verify ≥98% purity, Mass Spectrometry (MS) to confirm molecular weight, and LAL testing to ensure endotoxin levels remain below <0.01 EU/mg.
What are the recommended laboratory storage conditions for lyophilized Hexarelin?
Lyophilized Hexarelin should be stored in a freezer at -20°C or -80°C, protected from light and moisture. Following reconstitution with sterile bacteriostatic water or saline, aliquots should be refrigerated at 2°C to 8°C and used promptly.
Why is CD36 receptor affinity significant in Hexarelin research?
CD36 engagement allows researchers to explore non-endocrine cardioprotective pathways, such as ischemia-reperfusion injury recovery, lipid transport modulation, and reduction of oxidative stress in isolated cardiac tissue models.
What documentation accompanies Hexarelin orders from PX1 Research?
Each order includes a lot-specific Certificate of Analysis (COA) issued by an independent ISO 17025 accredited laboratory, displaying full HPLC chromatograms, mass spectrometry results, and endotoxin assay confirmation.
Can Hexarelin be administered to human subjects or used in clinical therapies?
No. Hexarelin is strictly synthesized and sold for laboratory research use only. It is not approved for human consumption, clinical diagnostic procedures, or veterinary applications.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.